Norwalk Leslie V sold $228K of NBIX
Norwalk Leslie V sold 1,250 shares of NEUROCRINE BIOSCIENCES INC (NBIX) at $182.01 ($0.23M total) on 2026-07-28 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The only disclosed event is a director open-market sale under a pre-arranged 10b5-1 plan; there is no accompanying guidance, trial update, or regulatory action.
Market read
Traders may note insider selling, but the 10b5-1 structure and lack of fundamental updates make this low-signal for price action.
What to watch
The article does not state whether other insiders sold/bought around the same window, nor does it provide total insider ownership changes beyond the post-transaction share count.
Background
The article is an SEC Form 4 insider transaction disclosure for Neurocrine Biosciences (NBIX).
Ticker impact
Norwalk Leslie V, a Neurocrine Biosciences director, sold 1,250 shares at $182.0060 on a 10b5-1 plan, totaling $227,507.50.
Likely minimal near-term impact; any effect is more about signaling than fundamentals.
The filing is a Form 4 insider transaction with an explicitly pre-arranged 10b5-1 plan, and the article provides no new company-specific news beyond the sale details.
Market effects
No sector read-through provided; this is company-specific insider trading disclosure.
None indicated.
None indicated.
Counterpoint
Because it is a 10b5-1 plan, the sale may reflect scheduled liquidity needs rather than bearish expectations.
Key entities
- issuerNEUROCRINE BIOSCIENCES INC
Company whose director insider sale is disclosed via Form 4.
- insiderNorwalk Leslie V
Director who sold 1,250 shares under a 10b5-1 plan.
